LSV Asset Management Buys Shares of 973,999 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

LSV Asset Management bought a new stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 973,999 shares of the biotechnology company’s stock, valued at approximately $10,889,000.

Other hedge funds have also added to or reduced their stakes in the company. Penserra Capital Management LLC grew its position in shares of Ironwood Pharmaceuticals by 173.1% during the fourth quarter. Penserra Capital Management LLC now owns 3,730 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 2,364 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in Ironwood Pharmaceuticals in the 1st quarter valued at about $63,000. Nisa Investment Advisors LLC lifted its stake in Ironwood Pharmaceuticals by 22.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 8,330 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 1,500 shares in the last quarter. Pinnacle Wealth Planning Services Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 1,545.8% in the 1st quarter. Pinnacle Wealth Planning Services Inc. now owns 10,352 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 9,723 shares during the period. Finally, Draper Asset Management LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $125,000.

A number of equities analysts recently commented on IRWD shares. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, April 20th. Morgan Stanley dropped their price objective on Ironwood Pharmaceuticals from $12.00 to $11.00 and set an “equal weight” rating on the stock in a report on Thursday, February 25th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average price target of $11.40.

In other Ironwood Pharmaceuticals news, Director Alexander J. Denner acquired 505,100 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, February 26th. The stock was bought at an average cost of $9.20 per share, with a total value of $4,646,920.00. Following the completion of the transaction, the director now owns 37,844 shares of the company’s stock, valued at $348,164.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alexander J. Denner acquired 75,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Wednesday, March 10th. The stock was acquired at an average cost of $10.54 per share, with a total value of $790,500.00. The disclosure for this purchase can be found here. Insiders bought 1,600,000 shares of company stock valued at $15,552,210 over the last three months. 2.40% of the stock is owned by company insiders.

Shares of IRWD stock opened at $11.16 on Thursday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $8.63 and a 12 month high of $12.55. The company has a quick ratio of 13.17, a current ratio of 13.17 and a debt-to-equity ratio of 71.91. The company has a market cap of $1.80 billion, a PE ratio of 16.17 and a beta of 1.46. The business’s 50 day moving average is $10.82 and its two-hundred day moving average is $10.90.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 6th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.02. Ironwood Pharmaceuticals had a negative return on equity of 240.80% and a net margin of 27.77%. The company had revenue of $88.80 million during the quarter, compared to analysts’ expectations of $87.94 million. During the same period in the prior year, the business earned $0.04 earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.68 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

See Also: Special Dividends

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.